How Boltz is Helping Build Better Molecules with Frontier AI

Boltz, helping every scientist reshape biology, led by Gabriele Corso, Jeremy Wohlwend, and Saro Passaro, announced its launch with $28 Million Seed Round from Zetta, Amplify, a16z, and strategic angels, including Clement Delangue (CEO of Hugging Face), Factorial Capital, and Obvious Ventures.

AI-powered molecular modeling is advancing rapidly, offering the potential to make biology programmable, digitize experiments, and accelerate drug development. However, emerging tools are increasingly closed, limiting scientific impact and slowing progress for patients.

Open models such as Boltz-1, Boltz-2, and BoltzGen have already reached more than 100,000 scientists and power pipelines across academia and industry. Fully realizing the potential of this technology requires robust products, scalable infrastructure, and interdisciplinary execution beyond the scope of academic environments.

Boltz PBC was created as a Public Benefit Corporation to advance frontier AI capabilities in biology through open science and to make these capabilities broadly accessible to scientists working toward a healthier, more sustainable future.

Major developments include the introduction of new small-molecule and protein design agents, the launch of Boltz Lab, the completion of a seed financing round, and the establishment of a strategic partnership with Pfizer.

Agents — The release of Boltz models sparked a wave of agentic workflows across academia and industry, but building reliable agents remains complex and sensitive to small design choices. Boltz is now developing a new generation of deeply integrated, rigorously validated agents for small-molecule and protein design. Early versions are now live on the platform with strong initial results from collaborator testing.

Boltz Lab — Boltz Lab is launching in preview as a unified environment for running the latest models and agents without high compute costs or infrastructure burdens. The platform delivers optimized performance, faster turnaround, and workflows aligned with real biology and chemistry needs, supported by clear data security and IP protections. With positive early feedback, Boltz Lab enters beta and continues to expand based on community use.

New Partnerships — Boltz PBC announced a multi-year collaboration with Pfizer to provide Boltz Lab and its agents to all Pfizer scientists and to leverage Pfizer’s data in building next-generation foundation models. In addition, the platform and new agents have already been deployed across multiple academic labs and companies, demonstrating their ability to support teams tackling complex targets in small-molecule and protein design projects. Early use shows the platform’s versatility across diverse research settings.